Table 3.

Survival models with parametric Weibull regression was completed stepwise for each incident musculoskeletal outcome to examine the effects of incremental adjustment on the exposure variable (SCI).

	Model 1	Model 2	Model 3	Model 4
Any Musculoskeletal	2.96 (2.83, 3.09)^***	2.76 (2.63, 2.88)^***	2.42 (2.32, 2.54)^***	2.41 (2.30, 2.52)^***
Osteoarthritis	2.46 (2.37, 2.56)^***	1.58 (1.52, 1.65)^***	1.31 (1.26, 1.36)^***	1.31 (1.26, 1.36)^***
Osteoporosis	3.89 (3.69, 4.09)^***	2.41 (2.29, 2.54)^***	2.20 (2.09, 2.32)^***	2.19 (2.08, 2.30)^***
Pathological fracture	13.28 (12.42, 14.20)^***	8.58 (8.04, 9.15)^***	7.09 (6.65, 7.56)^***	7.02 (6.58, 7.49)^***
Disorders of muscle, joint, ligaments, tendons, and connective tissues	2.68 (2.58, 2.78)^***	2.25 (2.17, 2.33)^***	1.94 (1.87, 2.02)^***	1.93 (1.86, 2.01)^***
Sarcopenia and weakness	5.80 (5.56, 6.05)^***	3.53 (3.39, 3.68)^***	2.68 (2.57, 2.80)^***	2.66 (2.55, 2.77)^***
Myalgia	1.92 (1.82, 2.03)^***	1.82 (1.72, 1.93)^***	1.47 (1.39, 1.55)^***	1.46 (1.38, 1.55)^***
Rheumatoid arthritis, myositis, and musculoskeletal infections	2.30 (2.08, 2.54)^***	1.62 (1.46, 1.79)^***	1.25 (1.13, 1.38)^***	1.26 (1.14, 1.39)^***

Model 1: Unadjusted

Model 2: Model 1 + Demographic variables (age, sex, race, geographic region).

Model 3: Model 1 + Model 2 + Modified Elixhauser Comorbidity Index

Model 4: Model 1 + Model 2 + Model 3 + Education + Income

As with incidence estimates (Table 2), all survival models used cases (SCI) and control cohorts consistent with Table 2, which required a one-year clean period with no evidence of the condition being measured

^***

P-value < 0.001